Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Liposarcoma 2Triple Negative Breast Neoplasms 1Tertiary Lymphoid Structures 1Sarcoma 1Histiocytoma, Malignant Fibrous 1Dermatofibrosarcoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1

Interventions

Doxorubicin 25Radiotherapy 15Ifosfamide 14Trabectedin 10pazopanib 6ribociclib 5pembrolizumab 5Specimen Handling 5Gemcitabine 5Biopsy 5palbociclib 4Magnetic Resonance Spectroscopy 4Docetaxel 4Chemotherapy, Adjuvant 4selinexor 3liposomal doxorubicin 3eribulin 3X-Rays 3Vincristine 3Radiation 3Neoadjuvant Therapy 3Imatinib Mesylate 3Filgrastim 3Etoposide 3Cyclophosphamide 3toripalimab 2temsirolimus 2romidepsin 2pegfilgrastim 2cixutumumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Liposarcoma × brigimadlin × Sarcoma × Clear all
NCT05218499 2026-03-02

Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

Boehringer Ingelheim

Phase 2/3 Completed
400 enrolled 15 charts
Sarcoma

Liposarcoma

NCT06058793 2026-01-09

Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma

Boehringer Ingelheim

Phase 3 Completed
138 enrolled
Sarcoma

Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡